For #GallbladderandBileDuctCancerAwarenessMonth, we examine current clinical standards for GBC. Management requires an aggressive multimodal approach.
• Localized 5-year OS: 69%
• Distant 5-year OS: 3%
Read more: https://bit.ly/3ZE0y31
#GBCAM #BiliaryTractCancer #Oncology #MedicalNews
For #GallbladderandBileDuctCancerAwarenessMonth, we highlight a Phase 2 trial of olaparib in patients with HRR mutations.
• 13.3% ORR
• 33.3% DCR
• Median PFS: 3.8 months
Read the review at: https://bit.ly/4rl7lul
#GBCAM #BiliaryTractCancer #Oncology #PrecisionMedicine
For #GallbladderandBileDuctCancerAwarenessMonth, we highlight the ACCORD trial: adjuvant camrelizumab, capecitabine, and RT improved outcomes in EHC and GBC.
• 3-year OS: 58.2% vs 30.5%
• HR: 0.43
Read the review: ➡️ https://bit.ly/40TETot
#GBCAM #BiliaryTractCancer #Oncology
Promotional banner for January 2026 announcing 30+ disease funds open, including for biliary tract cancer, hypercholesterolemia, and myasthenia gravis. Features Alicia, a PAN grant recipient living with myasthenia gravis, standing confidently.
Looking for #FinancialAssistance to cover your out-of-pocket medication costs? We currently have 30+ disease funds open—including #BiliaryTractCancer and #MyastheniaGravis—that you or a loved one may be eligible for.
👉 Explore our open funds: https://bit.ly/3e5B723
#OncoSky #MedSky
Two charts showing outcomes for biliary tract cancer patients. Top: survival probability over time for IHC 3+, IHC 2+, and overall. Bottom: bar graph of treatment-related adverse events, with diarrhea being the most frequent.
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/4rkG6jp
Zanidatamab (Baihe’an®): Un avance clave en el cáncer de vías biliares HER2 positivo
📩 info@dengyuemed.com
🔗https://dengyuepharma.com
#Zanidatamab #BaiheAn #HER2 #BiliaryTractCancer #Oncology #BispecificAntibody #TargetedTherapy #BreakthroughTherapy #CSCO #CDE #FDA
ZSAB-TOP, a phase 2 trial of first-line #Tislelizumab + Ociperlimab with GemCis in advanced #BiliaryTractCancer (BTC), shows encouraging tumor responses, survival outcomes, and a manageable safety profile. @fudan-university.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
Figure shows long-term outcomes for HER2+ advanced biliary tract cancer patients. Graph A shows overall survival probability over time for IHC 3+, IHC 2+, and overall patients. Graph B shows treatment-related adverse events (TRAEs) in ≥5% of patients. Diarrhea is the most common.
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/4oewULf
Brain MRI and CT scan showing an arachnoid cyst (arrowhead) along the orbital roof, erosion of the superior and lateral orbital walls, and mass effect from dural herniation.
For adults with metastatic HER2-positive #BiliaryTractCancer, zanidatamab led to longer overall survival and reduced pain, supporting its role as a precision therapy option. ja.ma/48pnesN
Single-centre (@petermaccc.bsky.social) real-world data on #BiliaryTractCancer: 1st line gem/cis+ICI yields outcomes comparable to pivotal trials. ECOG & albumin predict survival. #HER2 amp = worse OS; dMMR & #BRCA = trend toward improved OS. Study highlights importance of molecular profiling.
In fit older patients with advanced #biliarytractcancer, the combination chemotherapeutic regimen of GEM+CDDP+S-1 is associated with longer PFS compared with that of GEM+CDDP. Published in @gastroadvisor.bsky.social.
https://bit.ly/3KW5UlP
The Role of cfDNA in Biliary Tract Cancer: Clinical and Prognostic Perspectives
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #cfDNA #BiliaryTractCancer #BTC
Professor John Bridgewater appeared on the @simplyoncology podcast to raise awareness and provide more information about biliary tract cancers.
You can listen to the podcast here: ow.ly/MOKv50WWClL
#AMMF #bileductcancer #cholangiocarcinoma #CCA #biliarytractcancer
New draft protocol alert! 🚨 ASCO's "Treatment of Advanced #BiliaryTractCancer" is open for comments until September 24.
Share your feedback: brnw.ch/21wVMBd
New Survival Benchmark for People Living with Advanced Biliary Tract Cancer - Lorenza Rimassa
@lorenzarimassa.bsky.social
oncodaily.com/science/lore...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #GIOnc #BiliaryTractCancer
#gastrointestinalcancers #EC #JazzPharmaceuticals #Ziihera #zanidatamab #advancedbiliarytractcancer #biliarytractcancer #BTCpatients #HER2targetedbispecificantibody #HERIZONBTC01trial #gallbladdercancer #cholangiocarcinoma #advancedHER2positiveBTC #HER2targetedtherapy
pmlive.com/pharma_news/...
#ESMOGI25: Encouraging activity reported with olaparib in patients with advanced pretreated #BiliaryTractCancer and aberrant #HRR mutations, suggesting #PrecisionOncology may be a rational approach in this setting. Read more in the #ESMODailyReporter
🔗 buff.ly/i1NUMC9
If you or a loved one has a #BiliaryTractCancer, please take part in our new online surveys to share your experiences, preferences and priorities with #AMMF.
Patients: forms.gle/dQ5piqPeuTcf...
Partners/Family/Caregivers: forms.gle/Pn6Mb3Fs3EfE...
James J. Harding, MD, found zanidatamab led to ctDNA reductions in most patients with HER2+ #biliarytractcancer after 2 cycles, with 94% concordance between IHC 3+ and HER2 gene amplification in tumors. @mskcancercenter.bsky.social #ASCO25
Learn more: bit.ly/4jAUBvc
Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer
#BiliaryTractCancer #hpbcsm
www.onclive.com/view/zanidat...
Glad to be in Rio de Janeiro to discuss current and future treatment options for patients with #cholangiocarcinoma #biliarytractcancer #CCA #BTC. Thank you to everyone working to improve patient outcomes!
A real-world study from France highlights zanidatamab as a promising therapy for HER2-positive advanced biliary tract cancers ( #BTC ).
@eortc.org #EJC
#Onco404 #Cancer #Kanser #PrecisionMedicine #KişiyeÖzelTedavi #MedSky #OncSky #BiliaryTractCancer #HER2 #TargetedTherapy #MonoclonalAntibody
So grateful to have worked with this amazing group of friends and colleagues on #research priorities for #systemic therapies for #cholangiocarcinoma #biliarytractcancer #CCA #BTC @cholangiocarcinoma.bsky.social #HUNIMED #HUMANITAS @rachnatshroff.bsky.social @ardamanshergill.bsky.social
Ready for the @cholangiocarcinoma.bsky.social consensus conference on research priorities for #cholangiocarcinoma #CCA #biliarytractcancer #BTC #HumanitasUniversity #HUMANITASResearchHospital
On the final day of the #BiliaryTractCancer (BTC) Awareness Month, we are sharing a quote from Elisabeth Baucells Molera, the president of the Spanish Biliary Tract Cancer organisation, ATUVIBI.
Starting at 11:30 a.m. PST: #GI25 poster sessions! Stop by the West Hall for #pancreaticcancer and #biliarytractcancer advances by James Harding, Eileen O'Reilly, Rohit Thummalapalli, and Layal Al Mahmasani! @mskcancercenter.bsky.social @ascocancer.bsky.social
bit.ly/3WB5q7J
Night 1️⃣ of PeerView symposia at #GI25 was a success! 🎉 Congrats to Drs. Ghassan Abou-Alfa, Lipika Goyal, James J. Harding & Arndt Vogel on an amazing #BiliaryTractCancer session.
📌Tonight: HER2+ GI cancers & colorectal cancer—stay tuned!
Visit bit.ly/ASCOGIsky for more info!
#Oncsky #Medsky
Join us today in San Francisco at 6:00 PM PST for our #BiliaryTractCancer symposium, live in-person and virtual, during #ASCOGI2025. Share your questions in advance to @peerview.bsky.social View and get answers from our expert panel! bit.ly/Biliary-SF25T
FDA Novel Drug approvals in 2024 - Chris De Savi
@fda.gov
oncodaily.com/blog/215120
#Acoramidis #AcuteLeukemia #ArrhythmiaManagement #BiliaryTractCancer #Cancer #CancerCell #CellGrowth #DrugDiscovery #FDA #GeneticDisorders #Landiolol #Medicine #OncoDaily #Oncology #Revumenib #SVTtherapies
